Topics
Countries
Philippines News
Would you like to access news/blog content published by sources located in Philippines?
Code example
If you'd like to make a REST call, then make a following POST request:
Endpoint /api/v1/article/getArticles
Request body
{
"sourceLocationUri": "http://en.wikipedia.org/wiki/Philippines",
"resultType": "articles",
"apiKey": "API_KEY"
}
If you'd like instead to do a GET request then call:
/api/v1/article/getArticles?sourceLocationUri=http%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPhilippines&resultType=articles&apiKey=API_KEY
Example of JSON response
Below is an example JSON object that you would receive as the result of the request. You can retrieve also additional properties such as concepts, categories, source details, etc. by specifying additional parameters in the request as described on the documentation page.
{
"articles": {
"results": [
{
"uri": "9538477744",
"lang": "eng",
"isDuplicate": true,
"date": "2026-11-10",
"time": "12:42:27",
"dateTime": "2026-11-10T12:42:27Z",
"dateTimePub": "2026-11-10T12:35:57Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/form-83-advanced-medical-solutions-group-plc-octopus-investments/2466285",
"title": "Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments",
"body": "PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY\n\nA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE\n\nRule 8.3 of the Takeover Code (the \"Code\")\n\n1. KEY INFORMATION\n\n(a) Full name of discloser:OCTOPUS INVESTMENTS LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a):\n\nThe naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.\n\n(c) Name of offeror/offeree in relation to whose relevant securities this form relates:\n\nUse a separate form for each offeror/offeree\n\nAdvanced Medical Solutions Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:\n\nFor an opening position disclosure, state the latest practicable date prior to the disclosure\n\n09/11/2026(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?\n\nIf it is a cash offer or possible cash offer, state \"N/A\"\n\nNo\n\n2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE\n\nIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.\n\n(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)\n\nClass of relevant security:\n\nOrdinary 5p (GB0004536594) InterestsShort positions Number%Number%(1) Relevant securities owned and/or controlled:\n\n11,757,960\n\n5.32\n\n(2) Cash-settled derivatives:\n\n(3) Stock-settled derivatives (including options) and agreements to purchase/sell:\n\nTOTAL:\n\n11,757,9605.32 All interests and all short positions should be disclosed.\n\nDetails of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).\n\n(b) Rights to subscribe for new securities (including directors' and other employee options)\n\nClass of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE\n\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.\n\nThe currency of all prices and other monetary amounts should be stated.\n\n(a) Purchases and sales\n\nClass of relevant securityPurchase/sale\n\nNumber of securitiesPrice per unitOrdinary 5p\n\nSale\n\n18,390\n\n2.8275\n\n(b) Cash-settled derivative transactions\n\nClass of relevant securityProduct description\n\ne.g. CFD\n\nNature of dealing\n\ne.g. opening/closing a long/short position, increasing/reducing a long/short position\n\nNumber of reference securitiesPrice per unit (c) Stock-settled derivative transactions (including options)\n\n(i) Writing, selling, purchasing or varying\n\nClass of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType\n\ne.g. American, European etc.\n\nExpiry dateOption money paid/ received per unit (ii) Exercise\n\nClass of relevant securityProduct description\n\ne.g. call option\n\nExercising/ exercised againstNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities)\n\nClass of relevant securityNature of dealing\n\ne.g. subscription, conversion\n\nDetailsPrice per unit (if applicable) 4. OTHER INFORMATION\n\n(a) Indemnity and other dealing arrangements\n\nDetails of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:\n\nIrrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state \"none\"\n\nNone\n\n(b) Agreements, arrangements or understandings relating to options or derivatives\n\nDetails of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:\n\n(i) the voting rights of any relevant securities under any option; or\n\n(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:\n\nIf there are no such agreements, arrangements or understandings, state \"none\"\n\nNone\n\n(c) Attachments\n\nIs a Supplemental Form 8 (Open Positions) attached?NO\n\nDate of disclosure:10/11/2026Contact name:Andrea PentonTelephone number/email:[email protected]Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.\n\nThe Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.\n\nThe Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Derivative_(finance)",
"type": "wiki",
"score": 5,
"label": {
"eng": "Derivative (finance)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Short_(finance)",
"type": "wiki",
"score": 5,
"label": {
"eng": "Short (finance)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Security_(finance)",
"type": "wiki",
"score": 5,
"label": {
"eng": "Security (finance)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Settlor",
"type": "wiki",
"score": 3,
"label": {
"eng": "Settlor"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Octopus",
"type": "wiki",
"score": 3,
"label": {
"eng": "Octopus"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Trustee",
"type": "wiki",
"score": 3,
"label": {
"eng": "Trustee"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Investment_management",
"type": "wiki",
"score": 3,
"label": {
"eng": "Investment management"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Oregon",
"type": "loc",
"score": 3,
"label": {
"eng": "Oregon"
},
"location": {
"type": "place",
"label": {
"eng": "Oregon"
},
"country": {
"type": "country",
"label": {
"eng": "United States"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Currency",
"type": "wiki",
"score": 2,
"label": {
"eng": "Currency"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Call_option",
"type": "org",
"score": 1,
"label": {
"eng": "Call option"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Indemnity",
"type": "wiki",
"score": 1,
"label": {
"eng": "Indemnity"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Letter_of_intent",
"type": "wiki",
"score": 1,
"label": {
"eng": "Letter of intent"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Contract_for_difference",
"type": "wiki",
"score": 1,
"label": {
"eng": "Contract for difference"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Public_company",
"type": "wiki",
"score": 1,
"label": {
"eng": "Public company"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Nature_(journal)",
"type": "wiki",
"score": 1,
"label": {
"eng": "Nature (journal)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Suffrage",
"type": "wiki",
"score": 1,
"label": {
"eng": "Suffrage"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Email",
"type": "wiki",
"score": 1,
"label": {
"eng": "Email"
}
},
{
"uri": "http://en.wikipedia.org/wiki/United_States",
"type": "loc",
"score": 1,
"label": {
"eng": "United States"
},
"location": {
"type": "country",
"label": {
"eng": "United States"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Norway",
"type": "loc",
"score": 1,
"label": {
"eng": "Norway"
},
"location": {
"type": "country",
"label": {
"eng": "Norway"
}
}
}
],
"categories": [
{
"uri": "dmoz/Business/Investing/Stocks_and_Bonds",
"label": "dmoz/Business/Investing/Stocks and Bonds",
"wgt": 18
},
{
"uri": "dmoz/Society/Issues",
"label": "dmoz/Society/Issues",
"wgt": 17
},
{
"uri": "dmoz/Business/Investing/Brokerages",
"label": "dmoz/Business/Investing/Brokerages",
"wgt": 16
},
{
"uri": "dmoz/Business/Investing/Derivatives",
"label": "dmoz/Business/Investing/Derivatives",
"wgt": 26
},
{
"uri": "dmoz/Business/Investing/Clearing_Houses_and_Securities_Depositories",
"label": "dmoz/Business/Investing/Clearing Houses and Securities Depositories",
"wgt": 19
},
{
"uri": "news/Business",
"label": "news/Business",
"wgt": 97
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://cdnx.premiumread.com/?url=https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg&w=1920&q=75&f=webp&v=1",
"eventUri": null,
"sentiment": 0.5450980392156863,
"wgt": 532010547,
"relevance": 1
},
{
"uri": "9538477743",
"lang": "eng",
"isDuplicate": true,
"date": "2026-11-10",
"time": "12:42:27",
"dateTime": "2026-11-10T12:42:27Z",
"dateTimePub": "2026-11-10T12:35:58Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/salescloser-provides-commercial-update-recapping-four-us-patent-grants-ten-product-launches-and-global-customer-growth/2466286",
"title": "SalesCloser Provides Commercial Update Recapping Four U.S. Patent Grants, Ten Product Launches and Global Customer Growth",
"body": "Thirteen-application patent portfolio now includes four granted U.S. patents and one allowed application; nine-month revenue to June 30, 2026 rose 235% compared with the same period last year as customers expanded across at least eight countries and multiple industries.\n\nVancouver, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- SalesCloser Technologies Ltd. (\"SalesCloser\" or the \"Company\") (TSXV: SCAI) (OTCQB: SCTLF) (FSE: MJ5), a pioneer in autonomous AI sales technology, today provided a commercial update recapping six months of execution from late April through October 2026, consolidating previously announced milestones into a single view of the momentum built since the Company's TSX Venture Exchange listing in April 2026.\n\nHighlights (financial figures as reported in the Company's August 28, 2026 third quarter results):\n\n* Revenue of $1.13 million for the nine months ended June 30, 2026, up 235% from $0.34 million in the prior-year period\n\n* Four U.S. patents granted and a fifth allowed\n\n* Ten major product launches completed in six months\n\n* Enterprise deployments across insurance, hospitality, social media and software\n\n* Customers operating in at least eight countries\n\n* Gross margin increased to 72.6% for the nine months ended June 30, 2026 (compared with 59.5% in the prior-year period)\n\n* Cash of $3.8 million as at June 30, 2026, with no long-term debt As announced in the Company's August 28, 2026 third quarter results, revenue was $1,129,858 for the nine-month period ended June 30, 2026, an increase of 235% from $337,305 for the nine months ended June 30, 2025, with gross margin of 72.6% compared with 59.5% in the prior-year period. Cash was $3,778,297 at June 30, 2026, and the Company had no long-term debt as at that date. Revenue is diversifying geographically: for the nine-month period, 46% came from the United States, 17% from Canada, 7% from the United Kingdom and 30% from other markets, with more than one-third of revenue now generated outside North America. SalesCloser currently serves customers in at least eight countries, including the United States, Canada, Mexico, the United Kingdom, Australia, New Zealand, Spain and the Netherlands.\n\nCustomer adoption expanded during the six-month period from late April through October 2026, with deployments spanning insurance, hospitality, social media and software sectors. The Company secured engagements with enterprise organizations including a Latin American division of a top-ten global life insurer, a 270-room beachfront resort in North America and a top-five global social media platform. Named partners include Twilio to accelerate customer deployments, Xennox Solutions in the wellness, spa and resort sectors, and Tendril for autonomous AI engagement paired with human-assisted outbound dialing.\n\nProduct innovation translated directly into commercial expansion, with SalesCloser launching ten major platform enhancements during the six-month period designed to increase deployment flexibility, expand addressable markets and improve customer acquisition effectiveness. The Company deployed a dedicated GPU inference cluster on NVIDIA Blackwell-class hardware in Canada, running on a renewable hydroelectric grid, and introduced a self-serve multimodal AI website agent supporting more than 50 languages. Over the summer, the Company added a native HubSpot connector in June, handling of Apple iOS and Google Pixel call screening on outbound calls in June and July, live human takeover of AI calls in August and multi-party calls in September. In October, the Company launched Sky, which lets businesses build a live AI sales agent in minutes by talking to it, and added WhatsApp as a native channel so its AI sales agents can answer leads in seconds. The same month, SalesCloser introduced warm transfer to a teammate and launched its Model Context Protocol (MCP) server. Now listed in the official MCP Registry, the server lets AI assistants such as ChatGPT and Claude connect securely and work directly with SalesCloser's agents, leads and conversations. The Company also launched a Spanish-language website and internationalized the SalesCloser platform, starting with English and Spanish, so businesses can use SalesCloser in their own language.\n\nThe Company also continued to strengthen its intellectual property. The Company's U.S. patent portfolio now comprises thirteen applications: four granted patents, one allowed application and eight pending applications. The four grants were issued between January 13 and September 29, 2026, covering graph-based conversational-flow editing, adaptive voicemail and interactive voice response (IVR) detection, and memory management for appointment scheduling. A continuation of the adaptive voicemail and IVR detection filing received a Notice of Allowance and, if it issues, would become the Company's fifth granted U.S. patent. Two applications filed in 2026 cover capabilities already live in the platform: hybrid session management across text, voice and avatar channels, and dynamic multi-agent participation in live calls.\n\n\"Six months ago we were largely a single-product story,\" said Ali Tajskandar, Chief Executive Officer of SalesCloser. \"Since then, we've secured four U.S. patents with a fifth allowed, added customer engagements across insurance, hospitality, social media and software, delivered ten product launches, and expanded revenue to at least eight countries. We believe that breadth sets the foundation for continued growth.\"\n\nAbout SalesCloser\n\nSalesCloser.ai is a Vancouver-based AI software company focused on automating and scaling revenue generation through conversational AI. The Company's platform enables businesses to deploy AI-powered virtual sales agents that engage prospects and customers across the sales lifecycle. SalesCloser's agents conduct real-time, personalized interactions across voice, video, and digital channels, including lead qualification, product demonstrations, follow-ups, and meeting scheduling. By augmenting core sales functions, the platform is designed to help organizations increase capacity, accelerate pipeline velocity, and improve conversion rates without a corresponding increase in headcount. The platform integrates with existing CRM and business systems, supports multilingual deployment, and is intended to deliver consistent customer interactions across industries. SalesCloser operates under a subscription-based SaaS model, generating recurring revenue, while continuing to develop its AI capabilities. The Company's technology is supported by a growing portfolio of patents and patent applications focused on improving the performance of AI-driven conversational workflows. SalesCloser.ai is listed on the TSX Venture Exchange under the ticker \"SCAI\", on the OTCQB Venture Market under the ticker \"SCTLF\", and on the Frankfurt Stock Exchange under the ticker \"MJ5\". For more information, visit the SalesCloser investor site at: https://investors.salescloser.ai\n\nCorporate Contact\n\nJacky He, Chief Financial Officer\n\nEmail: [email protected]\n\nPhone: 778-655-4329\n\nInvestor Relations Contact\n\nArx Investor Relations\n\nNorth American Equities Desk\n\nForward-Looking Statements\n\nStatements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable Canadian securities laws (collectively, \"forward-looking statements\"). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about: the commercial update and the anticipated benefits of the Company's intellectual property portfolio, including the potential issuance of the allowed application and the pending patent applications; the expected adoption and benefits of the Company's product launches, including Sky, the self-serve multimodal AI website agent and the WhatsApp channel; customer adoption, engagement, retention and expansion across industry verticals and geographies; the Company's ability to expand its international footprint and the geographic diversification of its revenue; revenue growth and recurring SaaS revenue and expectations regarding future financial performance; technology development initiatives; commercial expansion and go-to-market strategies; future profitability; business opportunities, objectives, and prospects; and future events and performance. Sentences containing words such as \"expect\", \"anticipate\", \"plan\", \"continue\", \"estimate\", \"intend\", \"may\", \"will\", \"project\", \"predict\", \"potential\", \"is designed to\", \"strategy\", \"should\", \"believe\", \"contemplate\" and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on material assumptions, including that the Company's products and features will perform as designed and achieve commercial adoption, continued demand for conversational AI, the Company's ability to attract and retain customers and platform partners, the continued availability of third-party platforms and cloud infrastructure, and general economic conditions. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and based on current market trends and analysis of management, such statements are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including, but not limited to: risks that the Company's products or features do not perform as expected, experience technical difficulties, or fail to achieve commercial adoption; risks associated with delays in the development or rollout of new products and features; risks that the Company's pending or allowed patent applications do not result in issued patents, and that third parties develop competing technology or assert intellectual property infringement; risks relating to the Company's dependence on any single customer or group of customers; risks associated with the Company's international expansion, including foreign currency, regulatory and operational risks; risks that the Company does not achieve its revenue growth, gross margin or other objectives; changes to customer preferences and demand for conversational AI; competition from larger technology companies or other conversational AI providers; reliance on third-party service providers, cloud infrastructure, and software platforms; changes to the Company's revenue and profitability; data security, privacy, and regulatory compliance risks; economic uncertainty, inflation, interest rate fluctuations, and recessionary risks; and the additional risk factors discussed in the continuous disclosure materials of the Company available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update or revise them, except as required by law.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Hospitality",
"type": "wiki",
"score": 5,
"label": {
"eng": "Hospitality"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Patent",
"type": "wiki",
"score": 5,
"label": {
"eng": "Patent"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Software",
"type": "wiki",
"score": 5,
"label": {
"eng": "Software"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Artificial_intelligence",
"type": "wiki",
"score": 5,
"label": {
"eng": "Artificial intelligence"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Insurance",
"type": "wiki",
"score": 5,
"label": {
"eng": "Insurance"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Social_media",
"type": "wiki",
"score": 5,
"label": {
"eng": "Social media"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Canada",
"type": "loc",
"score": 5,
"label": {
"eng": "Canada"
},
"location": {
"type": "country",
"label": {
"eng": "Canada"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Patent_portfolio",
"type": "wiki",
"score": 4,
"label": {
"eng": "Patent portfolio"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Gross_margin",
"type": "wiki",
"score": 4,
"label": {
"eng": "Gross margin"
}
},
{
"uri": "http://en.wikipedia.org/wiki/TSX_Venture_Exchange",
"type": "wiki",
"score": 4,
"label": {
"eng": "TSX Venture Exchange"
}
},
{
"uri": "http://en.wikipedia.org/wiki/North_America",
"type": "loc",
"score": 4,
"label": {
"eng": "North America"
},
"location": null
},
{
"uri": "http://en.wikipedia.org/wiki/Revenue",
"type": "wiki",
"score": 4,
"label": {
"eng": "Revenue"
}
},
{
"uri": "http://en.wikipedia.org/wiki/United_States",
"type": "loc",
"score": 4,
"label": {
"eng": "United States"
},
"location": {
"type": "country",
"label": {
"eng": "United States"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/United_Kingdom",
"type": "loc",
"score": 4,
"label": {
"eng": "United Kingdom"
},
"location": {
"type": "country",
"label": {
"eng": "United Kingdom"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Voicemail",
"type": "wiki",
"score": 3,
"label": {
"eng": "Voicemail"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Interactive_voice_response",
"type": "wiki",
"score": 3,
"label": {
"eng": "Interactive voice response"
}
},
{
"uri": "http://en.wikipedia.org/wiki/OTC_Markets_Group",
"type": "org",
"score": 3,
"label": {
"eng": "OTC Markets Group"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Server_(computing)",
"type": "wiki",
"score": 3,
"label": {
"eng": "Server (computing)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Twilio",
"type": "wiki",
"score": 3,
"label": {
"eng": "Twilio"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Life_insurance",
"type": "wiki",
"score": 3,
"label": {
"eng": "Life insurance"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Latin_America",
"type": "loc",
"score": 3,
"label": {
"eng": "Latin America"
},
"location": null
},
{
"uri": "http://en.wikipedia.org/wiki/Spanish_language",
"type": "wiki",
"score": 3,
"label": {
"eng": "Spanish language"
}
},
{
"uri": "http://en.wikipedia.org/wiki/GlobeNewswire",
"type": "org",
"score": 3,
"label": {
"eng": "GlobeNewswire"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Vancouver",
"type": "loc",
"score": 3,
"label": {
"eng": "Vancouver"
},
"location": {
"type": "place",
"label": {
"eng": "Vancouver"
},
"country": {
"type": "country",
"label": {
"eng": "Canada"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/New_Zealand",
"type": "loc",
"score": 3,
"label": {
"eng": "New Zealand"
},
"location": {
"type": "country",
"label": {
"eng": "New Zealand"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Netherlands",
"type": "loc",
"score": 3,
"label": {
"eng": "Netherlands"
},
"location": {
"type": "country",
"label": {
"eng": "Netherlands"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Mexico",
"type": "loc",
"score": 3,
"label": {
"eng": "Mexico"
},
"location": {
"type": "country",
"label": {
"eng": "Mexico"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Spain",
"type": "loc",
"score": 3,
"label": {
"eng": "Spain"
},
"location": {
"type": "country",
"label": {
"eng": "Spain"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Australia",
"type": "loc",
"score": 3,
"label": {
"eng": "Australia"
},
"location": {
"type": "country",
"label": {
"eng": "Australia"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/ChatGPT",
"type": "wiki",
"score": 2,
"label": {
"eng": "ChatGPT"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Google_Pixel",
"type": "wiki",
"score": 2,
"label": {
"eng": "Google Pixel"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chatbot",
"type": "wiki",
"score": 2,
"label": {
"eng": "Chatbot"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Memory_management",
"type": "wiki",
"score": 2,
"label": {
"eng": "Memory management"
}
},
{
"uri": "http://en.wikipedia.org/wiki/HubSpot",
"type": "org",
"score": 2,
"label": {
"eng": "HubSpot"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Nvidia",
"type": "org",
"score": 2,
"label": {
"eng": "Nvidia"
}
},
{
"uri": "http://en.wikipedia.org/wiki/WhatsApp",
"type": "org",
"score": 2,
"label": {
"eng": "WhatsApp"
}
}
],
"categories": [
{
"uri": "dmoz/Business",
"label": "dmoz/Business",
"wgt": 29
},
{
"uri": "dmoz/Computers",
"label": "dmoz/Computers",
"wgt": 26
},
{
"uri": "dmoz/Society/Issues",
"label": "dmoz/Society/Issues",
"wgt": 22
},
{
"uri": "dmoz/Science/Technology",
"label": "dmoz/Science/Technology",
"wgt": 21
},
{
"uri": "dmoz/Science/Social_Sciences",
"label": "dmoz/Science/Social Sciences",
"wgt": 20
},
{
"uri": "news/Business",
"label": "news/Business",
"wgt": 100
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300515.png",
"eventUri": null,
"sentiment": 0.3960784313725489,
"wgt": 532010547,
"relevance": 1
},
{
"uri": "9538477745",
"lang": "eng",
"isDuplicate": true,
"date": "2026-11-10",
"time": "12:42:27",
"dateTime": "2026-11-10T12:42:27Z",
"dateTimePub": "2026-11-10T12:35:55Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/what-the-canada-growth-incentive-means-for-canadian-entrepreneurs-finance-bdc-and-founders-join-national-angel-capital-organization-national-briefing/2466284",
"title": "What the Canada Growth Incentive Means for Canadian Entrepreneurs: Finance, BDC and Founders Join National Angel Capital Organization National Briefing",
"body": "More than 900 investors, founders and ecosystem leaders have registered for today's online briefing on the Canada Growth Incentive and the new $75 million pre-seed and seed stream\n\nTORONTO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- The National Angel Capital Organization (NACO) will host a national briefing and roundtable today at noon ET on the Canada Growth Incentive and what Budget 2026 means for risk capital in Canada. Introduced in Budget 2026, the Canada Growth Incentive provides a tax exemption on up to $15 million in capital gains for investors in Canadian companies. The briefing will also address the federal Venture Capital Strategy, which for the first time starts at pre-seed, with a new $75 million pre-seed and seed investment stream.\n\n[PHOTO 1: National-Angel-Capital-Organization-Canada-Growth-Incentive-briefing-speakers-EN.png]\n\nCaption: Speakers at the National Angel Capital Organization's national briefing on the Canada Growth Incentive, Tuesday, November 10, 2026, at noon ET: Ryan Turnbull, Parliamentary Secretary to the Minister of Finance and National Revenue; Isabelle Hudon, President and CEO, BDC; Eliot Pence, Founder and CEO, Dominion Dynamics; Amanda Hall, Founder and CEO, Summit Lithium Technologies; and Chris Anderson, Partner, Davies.\n\nWHAT: National Briefing and Roundtable: Starting at Pre-Seed: What the Venture Capital Strategy and Budget 2026 Mean for Risk Capital in Canada\n\nWHO:\n\n* Ryan Turnbull, Parliamentary Secretary to the Minister of Finance and National Revenue\n\n* Isabelle Hudon, President and CEO, BDC, the bank for Canadian entrepreneurs\n\n* Eliot Pence, Founder and CEO, Dominion Dynamics, a Canadian defence technology company building Canada's sovereign defence future\n\n* Amanda Hall, Founder and CEO, Summit Lithium Technologies, building the infrastructure layer for the energy transition\n\n* Chris Anderson, Partner, Davies, a leading Canadian law firm\n\n* Moderated by Claudio Rojas, CEO of the National Angel Capital OrganizationWHEN: Tuesday, November 10, 2026, 12:00 to 1:30 p.m. ET. The speaker discussion runs from 12:00 to 1:00 p.m. ET, followed by a question period until 1:30 p.m. ET.\n\nWHERE: Online (Zoom Webinar). Media may register at join.nacocanada.com. Live attendance is limited to 1,000, so media are encouraged to register in advance and join from 11:55 a.m. ET. The session will be held primarily in English.\n\nMEDIA AVAILABILITY: Claudio Rojas, CEO of the National Angel Capital Organization, will be available for interviews following the briefing. Interview requests may be sent to [email protected].\n\nKey facts\n\n* More than 900 investors, founders and ecosystem leaders have registered for the briefing.\n\n* The Canada Growth Incentive, introduced in Budget 2026, provides a tax exemption on up to $15 million in capital gains for investors in Canadian companies.\n\n* The federal Venture Capital Strategy includes a new $75 million stream for pre-seed and seed investment, the first time the strategy reaches the earliest stage of company building.\n\n* The National Angel Capital Organization's network represents more than 4,000 angel investors and more than 100 angel networks and early-stage investment organizations, whose members have collectively invested more than $1.92 billion in over 3,000 Canadian ventures.About National Angel Capital Organization\n\nEstablished in 2002, the National Angel Capital Organization (NACO) represents more than 4,000 angel investors and over 100 angel networks and early-stage investment organizations across Canada. Its members have collectively invested more than $1.92 billion in over 3,000 Canadian ventures, supporting the founders building Canada's next generation of high-growth companies.\n\nWith deep domain expertise at the pre-seed and seed investment stages, NACO mobilizes risk capital for Canada's high-growth companies. Through NACO Academy, NACO Summit and national initiatives that connect entrepreneurs with investors in every region, it is building the investor base Canada needs to grow its next generation of global companies. Learn more at nacocanada.com.\n\nA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9b8b0a77-659f-41f0-bf11-2526145272b4\n\nCONTACT: Media contact\n\nClaudio Rojas\n\nCEO, National Angel Capital Organization",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/National_Angel_Capital_Organization",
"type": "wiki",
"score": 5,
"label": {
"eng": "National Angel Capital Organization"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Business_Development_Bank_of_Canada",
"type": "org",
"score": 5,
"label": {
"eng": "Business Development Bank of Canada"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Privately_held_company",
"type": "wiki",
"score": 5,
"label": {
"eng": "Privately held company"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Streaming_media",
"type": "wiki",
"score": 5,
"label": {
"eng": "Streaming media"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer",
"type": "wiki",
"score": 5,
"label": {
"eng": "Chief executive officer"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Canada",
"type": "loc",
"score": 5,
"label": {
"eng": "Canada"
},
"location": {
"type": "country",
"label": {
"eng": "Canada"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Ryan_Turnbull",
"type": "person",
"score": 4,
"label": {
"eng": "Ryan Turnbull"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Venture_capital",
"type": "wiki",
"score": 4,
"label": {
"eng": "Venture capital"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Khoros,_LLC",
"type": "wiki",
"score": 3,
"label": {
"eng": "Khoros, LLC"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Isabelle_Hudon",
"type": "person",
"score": 3,
"label": {
"eng": "Isabelle Hudon"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chris_Anderson_(entrepreneur)",
"type": "person",
"score": 3,
"label": {
"eng": "Chris Anderson (entrepreneur)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Minister_of_Finance_(Canada)",
"type": "wiki",
"score": 3,
"label": {
"eng": "Minister of Finance (Canada)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/The_National_(Abu_Dhabi)",
"type": "wiki",
"score": 3,
"label": {
"eng": "The National (Abu Dhabi)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Parliamentary_secretary",
"type": "wiki",
"score": 3,
"label": {
"eng": "Parliamentary secretary"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Seed_money",
"type": "wiki",
"score": 3,
"label": {
"eng": "Seed money"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Dominion",
"type": "wiki",
"score": 3,
"label": {
"eng": "Dominion"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Tax_exemption",
"type": "wiki",
"score": 3,
"label": {
"eng": "Tax exemption"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Capital_gain",
"type": "wiki",
"score": 3,
"label": {
"eng": "Capital gain"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Ecosystem",
"type": "wiki",
"score": 3,
"label": {
"eng": "Ecosystem"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Revenue",
"type": "wiki",
"score": 3,
"label": {
"eng": "Revenue"
}
},
{
"uri": "http://en.wikipedia.org/wiki/GlobeNewswire",
"type": "org",
"score": 3,
"label": {
"eng": "GlobeNewswire"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Zoom_(software)",
"type": "wiki",
"score": 2,
"label": {
"eng": "Zoom (software)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Claudio_Rojas",
"type": "person",
"score": 2,
"label": {
"eng": "Claudio Rojas"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Technology_company",
"type": "wiki",
"score": 2,
"label": {
"eng": "Technology company"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Law_firm",
"type": "wiki",
"score": 2,
"label": {
"eng": "Law firm"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Sovereignty",
"type": "wiki",
"score": 2,
"label": {
"eng": "Sovereignty"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Entrepreneurship",
"type": "wiki",
"score": 2,
"label": {
"eng": "Entrepreneurship"
}
}
],
"categories": [
{
"uri": "dmoz/Business/Financial_Services/Investment_Banks",
"label": "dmoz/Business/Financial Services/Investment Banks",
"wgt": 23
},
{
"uri": "dmoz/Business/Financial_Services/Venture_Capital",
"label": "dmoz/Business/Financial Services/Venture Capital",
"wgt": 40
},
{
"uri": "dmoz/Business/Small_Business/Start_Up",
"label": "dmoz/Business/Small Business/Start Up",
"wgt": 21
},
{
"uri": "dmoz/Business/Investing/Guides",
"label": "dmoz/Business/Investing/Guides",
"wgt": 22
},
{
"uri": "dmoz/Business/Financial_Services/Investment_Services",
"label": "dmoz/Business/Financial Services/Investment Services",
"wgt": 21
},
{
"uri": "news/Business",
"label": "news/Business",
"wgt": 93
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300512.jpg",
"eventUri": null,
"sentiment": 0.2862745098039217,
"wgt": 532010547,
"relevance": 1
},
{
"uri": "9538477741",
"lang": "eng",
"isDuplicate": false,
"date": "2026-11-10",
"time": "12:42:23",
"dateTime": "2026-11-10T12:42:23Z",
"dateTimePub": "2026-11-10T12:36:03Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/ardelyx-to-participate-at-the-jefferies-global-healthcare-conference-in-london/2466288",
"title": "Ardelyx to Participate at the Jefferies Global Healthcare Conference in London",
"body": "WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET.\n\nTo access the live webcast of the fireside chat, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available following the event.\n\nAbout Ardelyx\n\nArdelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company's pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.\n\nInvestor Contact:\n\nLisa Caperelli\n\nSVP, Investor Relations & Corporate Communications",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical",
"type": "wiki",
"score": 4,
"label": {
"eng": "Biopharmaceutical"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Fireside_chats",
"type": "wiki",
"score": 4,
"label": {
"eng": "Fireside chats"
}
},
{
"uri": "http://en.wikipedia.org/wiki/London",
"type": "loc",
"score": 4,
"label": {
"eng": "London"
},
"location": {
"type": "place",
"label": {
"eng": "London"
},
"country": {
"type": "country",
"label": {
"eng": "United Kingdom"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Nasdaq",
"type": "wiki",
"score": 3,
"label": {
"eng": "Nasdaq"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Webcast",
"type": "wiki",
"score": 3,
"label": {
"eng": "Webcast"
}
},
{
"uri": "http://en.wikipedia.org/wiki/GlobeNewswire",
"type": "org",
"score": 3,
"label": {
"eng": "GlobeNewswire"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Waltham,_Massachusetts",
"type": "loc",
"score": 3,
"label": {
"eng": "Waltham, Massachusetts"
},
"location": {
"type": "place",
"label": {
"eng": "Waltham, Massachusetts"
},
"country": {
"type": "country",
"label": {
"eng": "United States"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Enzyme_inhibitor",
"type": "wiki",
"score": 1,
"label": {
"eng": "Enzyme inhibitor"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Pipeline_transport",
"type": "wiki",
"score": 1,
"label": {
"eng": "Pipeline transport"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Constipation",
"type": "wiki",
"score": 1,
"label": {
"eng": "Constipation"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Facebook",
"type": "org",
"score": 1,
"label": {
"eng": "Facebook"
}
},
{
"uri": "http://en.wikipedia.org/wiki/LinkedIn",
"type": "org",
"score": 1,
"label": {
"eng": "LinkedIn"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Twitter",
"type": "org",
"score": 1,
"label": {
"eng": "Twitter"
}
},
{
"uri": "http://en.wikipedia.org/wiki/United_States",
"type": "loc",
"score": 1,
"label": {
"eng": "United States"
},
"location": {
"type": "country",
"label": {
"eng": "United States"
}
}
}
],
"categories": [
{
"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Pharmaceuticals",
"label": "dmoz/Business/Biotechnology and Pharmaceuticals/Pharmaceuticals",
"wgt": 23
},
{
"uri": "dmoz/Business/Healthcare",
"label": "dmoz/Business/Healthcare",
"wgt": 22
},
{
"uri": "dmoz/Business/Real_Estate/Development",
"label": "dmoz/Business/Real Estate/Development",
"wgt": 18
},
{
"uri": "dmoz/Business/Real_Estate/Commercial",
"label": "dmoz/Business/Real Estate/Commercial",
"wgt": 18
},
{
"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Consulting",
"label": "dmoz/Business/Biotechnology and Pharmaceuticals/Consulting",
"wgt": 16
},
{
"uri": "news/Business",
"label": "news/Business",
"wgt": 89
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300519.jpg",
"eventUri": null,
"sentiment": 0.3176470588235294,
"wgt": 532010543,
"relevance": 1
},
{
"uri": "9538477742",
"lang": "eng",
"isDuplicate": true,
"date": "2026-11-10",
"time": "12:42:23",
"dateTime": "2026-11-10T12:42:23Z",
"dateTimePub": "2026-11-10T12:36:00Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/from-one-time-transactions-to-full-lifecycle-engagement-how-chery-is-redefining-customer-relationships-through-its-global-family-approach/2466287",
"title": "From One-Time Transactions to Full-Lifecycle Engagement: How Chery Is Redefining Customer Relationships Through Its 'Global Family\" Approach",
"body": "WUHU, China, Nov. 10, 2026 (GLOBE NEWSWIRE) -- As automotive technology matures, competition is shifting from vehicle specifications toward lasting customer relationships. At the 2026 Chery International User Summit in October, approximately 2,000 users, dealers and ecosystem partners from more than 100 countries and regions gathered in Wuhu, underscoring Chery's commitment to transforming one-time purchases into long-term relationships grounded in trust, service and engagement.\n\nFrom Vehicle Delivery to Lasting Relationships\n\nFor Chery, vehicle delivery marks the beginning of customer engagement rather than the end of a transaction. Beyond manufacturing, the company emphasizes continuous software improvements, reliable services and meaningful connections with users. As performance standards improve across the industry, sustained customer relationships are becoming an increasingly important measure of enduring brand value.\n\n\"Global Family\": Turning User Feedback into Product Innovation\n\nChery gathers regional feedback through dynamic test-drive questionnaires and static vehicle design surveys. Experiences involving extreme heat, sandy conditions and congested traffic inform product definition, feature selection, vehicle calibration and optimization. This connects real-world vehicle use directly with the research and development process.\n\nFeedback from UAE owners on high-temperature performance and European customers on hybrid refinement and quietness can contribute to product development discussions. By integrating diverse market experiences into R&D, Chery positions users as active contributors to ongoing vehicle improvement, rather than simply recipients of finished products.\n\nEnd-to-End Co-Creation: Giving Users a Voice\n\nDuring the summit, iCAUR MODFEST incorporated regional customization preferences, FREELANDER conducted research into global user needs, and CHERY Brand invited users to vote on vehicle feature priorities during a product preview event.\n\nThese initiatives translate diverse design preferences and driving habits into structured co-creation processes. User feedback can thereby influence product decisions and development priorities, helping Chery create vehicles better suited to practical driving needs across international markets.\n\nFull-Lifecycle Engagement Across Cultures\n\nChery's \"Global Family\" philosophy emphasizes respect for different cultural backgrounds, aesthetic preferences and driving conditions. Over-the-air (OTA) software updates and a global service network support continued engagement throughout vehicle ownership, extending the relationship well beyond delivery.\n\nBy treating customer relationships as a long-term asset, Chery aims to build trust across markets and generations. Its approach reflects a broader industry shift toward customer experience, collaborative product development and sustained value beyond the initial sale.\n\nA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/486cad47-a7b2-4215-8013-6acd9fde8e4f\n\nCONTACT: Media Contact\n\nKara Wang\n\nSenior Brand Manager, Chery Automobile\n\nTel: +86 187 1530 2460",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Chery",
"type": "org",
"score": 5,
"label": {
"eng": "Chery"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Wuhu",
"type": "loc",
"score": 5,
"label": {
"eng": "Wuhu"
},
"location": {
"type": "place",
"label": {
"eng": "Wuhu"
},
"country": {
"type": "country",
"label": {
"eng": "China"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Customer_relationship_management",
"type": "wiki",
"score": 4,
"label": {
"eng": "Customer relationship management"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Automotive_engineering",
"type": "wiki",
"score": 3,
"label": {
"eng": "Automotive engineering"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Customer_engagement",
"type": "wiki",
"score": 3,
"label": {
"eng": "Customer engagement"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Ecosystem",
"type": "wiki",
"score": 3,
"label": {
"eng": "Ecosystem"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Research_and_development",
"type": "wiki",
"score": 3,
"label": {
"eng": "Research and development"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Feature_selection",
"type": "wiki",
"score": 2,
"label": {
"eng": "Feature selection"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Brand_valuation",
"type": "wiki",
"score": 2,
"label": {
"eng": "Brand valuation"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Mathematical_optimization",
"type": "wiki",
"score": 2,
"label": {
"eng": "Mathematical optimization"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Heat_wave",
"type": "wiki",
"score": 2,
"label": {
"eng": "Heat wave"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Hybrid_electric_vehicle",
"type": "wiki",
"score": 2,
"label": {
"eng": "Hybrid electric vehicle"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Software",
"type": "wiki",
"score": 2,
"label": {
"eng": "Software"
}
},
{
"uri": "http://en.wikipedia.org/wiki/United_Arab_Emirates",
"type": "loc",
"score": 2,
"label": {
"eng": "United Arab Emirates"
},
"location": {
"type": "country",
"label": {
"eng": "United Arab Emirates"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Product_development",
"type": "wiki",
"score": 1,
"label": {
"eng": "Product development"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Co-creation",
"type": "wiki",
"score": 1,
"label": {
"eng": "Co-creation"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Telephone_numbers_in_China",
"type": "wiki",
"score": 1,
"label": {
"eng": "Telephone numbers in China"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Brand_management",
"type": "wiki",
"score": 1,
"label": {
"eng": "Brand management"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Terrestrial_television",
"type": "wiki",
"score": 1,
"label": {
"eng": "Terrestrial television"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Customer_experience",
"type": "wiki",
"score": 1,
"label": {
"eng": "Customer experience"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Patch_(computing)",
"type": "wiki",
"score": 1,
"label": {
"eng": "Patch (computing)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Aesthetics",
"type": "wiki",
"score": 1,
"label": {
"eng": "Aesthetics"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Philosophy",
"type": "wiki",
"score": 1,
"label": {
"eng": "Philosophy"
}
}
],
"categories": [
{
"uri": "dmoz/Computers",
"label": "dmoz/Computers",
"wgt": 20
},
{
"uri": "dmoz/Science/Technology",
"label": "dmoz/Science/Technology",
"wgt": 20
},
{
"uri": "dmoz/Business/Business_Services/Customer_Management",
"label": "dmoz/Business/Business Services/Customer Management",
"wgt": 23
},
{
"uri": "dmoz/Business/Customer_Service/Software",
"label": "dmoz/Business/Customer Service/Software",
"wgt": 23
},
{
"uri": "dmoz/Business/Customer_Service/Consulting",
"label": "dmoz/Business/Customer Service/Consulting",
"wgt": 22
},
{
"uri": "news/Technology",
"label": "news/Technology",
"wgt": 89
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300516.jpg",
"eventUri": null,
"sentiment": 0.4745098039215687,
"wgt": 532010543,
"relevance": 1
},
{
"uri": "9538477738",
"lang": "eng",
"isDuplicate": false,
"date": "2026-11-10",
"time": "12:42:23",
"dateTime": "2026-11-10T12:42:23Z",
"dateTimePub": "2026-11-10T12:36:20Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences/2466291",
"title": "Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences",
"body": "CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2026:\n\n* Stifel 2026 Healthcare Conference: Fireside chat on Wednesday November 11, 2026, at 8:40 AM Eastern Time (ET) and investor meetings.\n\n* Jefferies Global Healthcare Conference: Presentation on Wednesday, November 18, 2026, at 10:30 AM Greenwich Mean Time (GMT) and investor meetings. Live webcasts of the fireside chat and Company presentation can be accessed on the Investors section of the Abeona website under \"Events\" at https://investors.abeonatherapeutics.com/events, where replays of available events will also be accessible for a limited time.\n\nAbout Abeona Therapeutics\n\nAbeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases with multiple opportunities for value creation. The Company's portfolio includes ZEVASKYN® (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa; ABO-801, a Phase 3-ready product candidate for eosinophilic esophagitis; and ABO-701 (PSMA-SIR-T™), an investigational engineered T-cell therapy targeting PSMA. For more information, visit www.abeonatherapeutics.com.\n\nZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.\n\nCONTACT: Contacts:\n\nInvestor and Media:\n\nGreg Gin\n\nVP, Investor Relations and Corporate Communications",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Fireside_chats",
"type": "wiki",
"score": 4,
"label": {
"eng": "Fireside chats"
}
},
{
"uri": "http://en.wikipedia.org/wiki/AM_broadcasting",
"type": "wiki",
"score": 4,
"label": {
"eng": "AM broadcasting"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Nasdaq",
"type": "wiki",
"score": 3,
"label": {
"eng": "Nasdaq"
}
},
{
"uri": "http://en.wikipedia.org/wiki/GlobeNewswire",
"type": "org",
"score": 3,
"label": {
"eng": "GlobeNewswire"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Cleveland",
"type": "loc",
"score": 3,
"label": {
"eng": "Cleveland"
},
"location": {
"type": "place",
"label": {
"eng": "Cleveland"
},
"country": {
"type": "country",
"label": {
"eng": "United States"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Webcast",
"type": "wiki",
"score": 2,
"label": {
"eng": "Webcast"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Greenwich",
"type": "loc",
"score": 2,
"label": {
"eng": "Greenwich"
},
"location": {
"type": "place",
"label": {
"eng": "Greenwich"
},
"country": {
"type": "country",
"label": {
"eng": "United Kingdom"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical",
"type": "wiki",
"score": 1,
"label": {
"eng": "Biopharmaceutical"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Eosinophilic_esophagitis",
"type": "wiki",
"score": 1,
"label": {
"eng": "Eosinophilic esophagitis"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Epidermolysis_bullosa",
"type": "wiki",
"score": 1,
"label": {
"eng": "Epidermolysis bullosa"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Dominance_(genetics)",
"type": "wiki",
"score": 1,
"label": {
"eng": "Dominance (genetics)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation",
"type": "wiki",
"score": 1,
"label": {
"eng": "Hematopoietic stem cell transplantation"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Gene_therapy",
"type": "wiki",
"score": 1,
"label": {
"eng": "Gene therapy"
}
},
{
"uri": "http://en.wikipedia.org/wiki/T_cell",
"type": "wiki",
"score": 1,
"label": {
"eng": "T cell"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Logo",
"type": "wiki",
"score": 1,
"label": {
"eng": "Logo"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Trademark",
"type": "wiki",
"score": 1,
"label": {
"eng": "Trademark"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Vice_president",
"type": "wiki",
"score": 1,
"label": {
"eng": "Vice president"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Pediatrics",
"type": "wiki",
"score": 1,
"label": {
"eng": "Pediatrics"
}
}
],
"categories": [
{
"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Pharmaceuticals",
"label": "dmoz/Business/Biotechnology and Pharmaceuticals/Pharmaceuticals",
"wgt": 19
},
{
"uri": "dmoz/Science/Biology/Cell_Biology",
"label": "dmoz/Science/Biology/Cell Biology",
"wgt": 19
},
{
"uri": "dmoz/Business/Marketing_and_Advertising/Public_Relations",
"label": "dmoz/Business/Marketing and Advertising/Public Relations",
"wgt": 18
},
{
"uri": "dmoz/Business/Investing/Guides",
"label": "dmoz/Business/Investing/Guides",
"wgt": 18
},
{
"uri": "dmoz/Business/Resources",
"label": "dmoz/Business/Resources",
"wgt": 22
},
{
"uri": "news/Business",
"label": "news/Business",
"wgt": 100
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300524.png",
"eventUri": null,
"sentiment": 0.05882352941176472,
"wgt": 532010543,
"relevance": 1
},
{
"uri": "9538477736",
"lang": "eng",
"isDuplicate": false,
"date": "2026-11-10",
"time": "12:42:23",
"dateTime": "2026-11-10T12:42:23Z",
"dateTimePub": "2026-11-10T12:36:22Z",
"dataType": "news",
"sim": 0.5843137502670288,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/exagen-inc-reports-third-quarter-2026-financial-results/2466293",
"title": "Exagen Inc. Reports Third Quarter 2026 Financial Results",
"body": "Third Quarter Revenue Grew 7% to $18.4 Million\n\nYear-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30%\n\nCARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a precision medicine company bringing clarity to autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and recent corporate updates.\n\nThree Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Unaudited. In thousands, except ASP data. Revenue $ 18,417 $ 17,244 $ 55,664 $ 49,944 Gross margin 58.8% 58.4% 59.7% 59.3%Operating expenses $ 15,244 $ 13,175 $ 42,802 $ 38,688 Operating loss $ (4,408) $ (3,100) $ (9,544) $ (9,095)Net loss $ (6,336) $ (7,087) $ (13,499) $ (15,278)Adjusted EBITDA $ (1,932) $ (1,895) $ (4,206) $ (6,124)Trailing twelve-month average selling price (ASP) $ 451 $ 441 $ 451 $ 441 Cash and cash equivalents (as of September 30) $ 28,092 $ 35,652 $ 28,092 $ 35,652\n\nThird Quarter 2026 and Recent Corporate Highlights:\n\n* Achieved total revenue of $18.4 million, an increase of 7% compared to third quarter 2025.\n\n* Expanded AVISE CTD trailing twelve-month ASP to $451 per test, an increase of $10 per test compared to third quarter 2025 and the 14th consecutive quarter of growth.\n\n* Ended the quarter with approximately $28.1 million in cash and cash equivalents.\n\n* Presented nine abstracts at the 2026 American College of Rheumatology (ACR) Convergence Conference, including two podium presentations on proprietary T-cell marker disease associations and an analysis of phenotypic patterns across more than 375,000 AVISE CTD tests. \"Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year,\" said John Aballi, President and Chief Executive Officer of Exagen. \"Beyond our financial performance, our strong showing at ACR Convergence demonstrates that our science continues to push the boundaries of traditional autoimmune care. We also remain on track to launch our myositis offering early in 2027, bringing greater clarity and confidence to clinicians and patients in an area of significant need.\"\n\nExagen Forward: Building the Autoimmune Platform\n\nThe company will host an educational webcast on December 15, 2026, at 12:00 p.m. ET (9:00 a.m. PT) to discuss the significant unmet clinical need in myositis, Exagen's unique myositis solution, and additional pipeline development efforts. Further details, including registration information, will be provided at a later date.\n\n2026 Guidance\n\nThe company reiterated full-year 2026 revenue guidance of $72 million to $75 million.\n\nConference Call and Webcast\n\nJohn Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a webcast at 8:00 a.m. ET (5:00 a.m. PT) this morning to review the results.\n\nThe webcast will be available on the Exagen Investor Relations website at investors.exagen.com. Participants wishing to join by phone should register in advance using the following link for dial-in instructions: https://register-conf.media-server.com/register/BId7f4a0dc53154d5e84d4eb39ccfa279d.\n\nA replay of the webcast will be available for 12 months via the Exagen Investor Relations website at investors.exagen.com.\n\nUse of Non-GAAP Financial Measures (Unaudited)\n\nIn addition to the financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release contains the metric adjusted EBITDA, which is not calculated in accordance with GAAP and is a non-GAAP financial measure. Adjusted EBITDA is defined as net loss adjusted for other income (expense), net, interest income (expense), income tax expense (benefit), depreciation and amortization expense, stock‑based compensation expense, change in fair value of warrant liability, acquired in-process research and development, and certain other non‑cash, unusual or non‑recurring items, including, for example, losses on extinguishment of debt; we do not exclude normal, recurring, cash operating expenses from this measure. Such items could have a significant impact on the calculation of GAAP net loss.\n\nExagen uses adjusted EBITDA internally because the company believes this measure provides useful supplemental information in addition to its operating performance reported in accordance with GAAP. Exagen believes adjusted EBITDA may enhance an evaluation of the operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses the company believes are not indicative of the ongoing performance. However, this non-GAAP financial measure may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes.\n\nThis non-GAAP financial measure is not meant to be considered in isolation or used as a substitute for net loss reported in accordance with GAAP, should be considered in conjunction with the financial information presented in accordance with GAAP, has no standardized meaning prescribed by GAAP, is unaudited, and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that Exagen may exclude for purposes of these non-GAAP financial measures, and the company may in the future cease to exclude items that it has historically excluded for purposes of these non-GAAP financial measures. Likewise, Exagen may determine to modify the nature of adjustments to arrive at these non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by the company in this press release and the accompanying reconciliation table have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures.\n\nA reconciliation of net loss to non-GAAP adjusted EBITDA is provided in the financial schedules that are part of this press release.\n\nAbout Exagen\n\nExagen Inc. (Nasdaq: XGN) is a specialized diagnostics company with an autoimmune platform that empowers physicians to make more confident decisions, earlier. Its flagship test, AVISE® CTD, provides diagnostic clarity in complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's disease. Based in San Diego County, California, Exagen operates a CLIA-certified, CAP-accredited rheumatology laboratory delivering precise, timely results to physicians and partners across healthcare and biopharma. Through ongoing research and innovation, Exagen is committed to advancing care for autoimmune disease.\n\nForward-Looking Statements\n\nExagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as \"anticipate,\" \"believe,\" \"expect,\" \"guidance,\" \"intend,\" \"may,\" \"on track,\" \"plan,\" \"will\" and similar expressions are intended to identify forward-looking statements. These statements are based on Exagen's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen's goals, strategies, positioning and ambitions; evaluations and judgments regarding financial results and the potential implications of those results; potential future financial and business performance, including any improvements to adjusted EBITDA, ASP, net loss and potential profitability; the potential utility and effectiveness of Exagen's services and testing solutions; the timing of Exagen's myositis and pipeline development; the impact of Exagen's revenue cycle management strategy on the timing of collections and cash burn; potential stockholder value and growth; and full-year 2026 revenue guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen's business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; the potential effects of inflation and tariffs on Exagen's margins; changes in laws and regulations related to Exagen's regulatory requirements; fluctuations in the fair value of its warrant liability; Exagen's commercial success, which depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen's ability to successfully execute on its business strategies; Exagen's ability to obtain additional funding; third-party payors not providing coverage and adequate reimbursement for Exagen's testing products, including Exagen's ability to collect on funds due; Exagen's ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen's business; and other risks described in Exagen's filings with the Securities and Exchange Commission (SEC), including under the heading \"Risk Factors\" in Exagen's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 10, 2026, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, filed with the SEC on May 11, 2026, August 4, 2026, and November 10, 2026, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\n\nInvestors:\n\nTina Jacobsen, CFA\n\nExagen Inc.\n\nExagen Inc.\n\nUnaudited Condensed Consolidated Statements of Operations\n\n(in thousands, except share and per share amounts)\n\nThree Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Revenue $ 18,417 $ 17,244 $ 55,664 $ 49,944 Cost of revenue 7,581 7,169 22,406 20,351 Gross profit 10,836 10,075 33,258 29,593 Operating expenses: Selling, general and administrative expenses 12,834 11,445 37,413 34,191 Research and development expenses 1,823 1,730 4,802 4,497 In-process research and development expenses* 587 - 587 - Total operating expenses 15,244 13,175 42,802 38,688 Loss from operations (4,408) (3,100) (9,544) (9,095)Interest expense (1,201) (1,319) (3,669) (2,988)Loss on extinguishment of debt - - - (295)Change in fair value of warrant liability (909) (2,670) (453) (3,108)Other income (expense), net 181 3 202 246 Loss before income taxes (6,337) (7,086) (13,464) (15,240)Income tax (expense) benefit 1 (1) (35) (38)Net loss $ (6,336) $ (7,087) $ (13,499",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Accounting_standard",
"type": "wiki",
"score": 5,
"label": {
"eng": "Accounting standard"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Myositis",
"type": "wiki",
"score": 5,
"label": {
"eng": "Myositis"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Autoimmunity",
"type": "wiki",
"score": 5,
"label": {
"eng": "Autoimmunity"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Cash_and_cash_equivalents",
"type": "wiki",
"score": 5,
"label": {
"eng": "Cash and cash equivalents"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Webcast",
"type": "wiki",
"score": 5,
"label": {
"eng": "Webcast"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Earnings_before_interest,_taxes,_depreciation,_and_amortization",
"type": "wiki",
"score": 5,
"label": {
"eng": "Earnings before interest, taxes, depreciation, and amortization"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Revenue",
"type": "wiki",
"score": 5,
"label": {
"eng": "Revenue"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Nasdaq",
"type": "wiki",
"score": 4,
"label": {
"eng": "Nasdaq"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Autoimmune_disease",
"type": "wiki",
"score": 4,
"label": {
"eng": "Autoimmune disease"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer",
"type": "wiki",
"score": 4,
"label": {
"eng": "Chief executive officer"
}
},
{
"uri": "http://en.wikipedia.org/wiki/American_College_of_Rheumatology",
"type": "wiki",
"score": 3,
"label": {
"eng": "American College of Rheumatology"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Phenotype",
"type": "wiki",
"score": 3,
"label": {
"eng": "Phenotype"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Personalized_medicine",
"type": "wiki",
"score": 3,
"label": {
"eng": "Personalized medicine"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Operating_expense",
"type": "wiki",
"score": 3,
"label": {
"eng": "Operating expense"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Gross_margin",
"type": "wiki",
"score": 3,
"label": {
"eng": "Gross margin"
}
},
{
"uri": "http://en.wikipedia.org/wiki/T_cell",
"type": "wiki",
"score": 3,
"label": {
"eng": "T cell"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Property",
"type": "wiki",
"score": 3,
"label": {
"eng": "Property"
}
},
{
"uri": "http://en.wikipedia.org/wiki/GlobeNewswire",
"type": "org",
"score": 3,
"label": {
"eng": "GlobeNewswire"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Carlsbad,_California",
"type": "loc",
"score": 3,
"label": {
"eng": "Carlsbad, California"
},
"location": {
"type": "place",
"label": {
"eng": "Carlsbad, California"
},
"country": {
"type": "country",
"label": {
"eng": "United States"
}
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/Amortization_(accounting)",
"type": "wiki",
"score": 2,
"label": {
"eng": "Amortization (accounting)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Accounting",
"type": "wiki",
"score": 2,
"label": {
"eng": "Accounting"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Fair_value",
"type": "wiki",
"score": 2,
"label": {
"eng": "Fair value"
}
},
{
"uri": "http://en.wikipedia.org/wiki/United_States",
"type": "loc",
"score": 2,
"label": {
"eng": "United States"
},
"location": {
"type": "country",
"label": {
"eng": "United States"
}
}
},
{
"uri": "http://en.wikipedia.org/wiki/San_Diego_County,_California",
"type": "loc",
"score": 1,
"label": {
"eng": "San Diego County, California"
},
"location": {
"type": "place",
"label": {
"eng": "San Diego County, California"
},
"country": {
"type": "country",
"label": {
"eng": "United States"
}
}
}
}
],
"categories": [
{
"uri": "dmoz/Business/Investing",
"label": "dmoz/Business/Investing",
"wgt": 24
},
{
"uri": "dmoz/Society/Issues/Business",
"label": "dmoz/Society/Issues/Business",
"wgt": 26
},
{
"uri": "dmoz/Home/Personal_Finance",
"label": "dmoz/Home/Personal Finance",
"wgt": 21
},
{
"uri": "dmoz/Business/Financial_Services/Information_Services",
"label": "dmoz/Business/Financial Services/Information Services",
"wgt": 20
},
{
"uri": "dmoz/Business/Major_Companies/Company_Information",
"label": "dmoz/Business/Major Companies/Company Information",
"wgt": 22
},
{
"uri": "news/Business",
"label": "news/Business",
"wgt": 100
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300526.jpg",
"eventUri": "eng-12174595",
"sentiment": 0.1607843137254903,
"wgt": 532010543,
"relevance": 1
},
{
"uri": "9538477739",
"lang": "eng",
"isDuplicate": false,
"date": "2026-11-10",
"time": "12:42:23",
"dateTime": "2026-11-10T12:42:23Z",
"dateTimePub": "2026-11-10T12:36:19Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/kalaris-reports-third-quarter-2026-financial-results-and-provides-business-update/2466290",
"title": "Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update",
"body": "Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027\n\nRecently completed technology transfer from pilot to commercial-scale manufacturer with test batches meeting target specifications\n\n$82.9 million in cash, cash equivalents and marketable securities as of September 30, 2026 now expected to fund operations into 2028\n\nBERKELEY HEIGHTS, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (\"Kalaris\"), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.\n\nBusiness Updates\n\n* Kalaris continues to enroll a Phase 1b/2, multiple-ascending dose, dose-finding study evaluating up to four monthly loading doses of TH103 in patients with neovascular age-related macular degeneration (nAMD). The study aims to assess the safety and efficacy of repeat doses of TH103 in approximately 60-80 patients at different dose levels and to identify the optimal dose for potential Phase 3 development.\n\n* In the third quarter, the pilot manufacturer for clinical supply of TH103 produced a batch that did not meet the applicable release specification for aggregation due to a batch-specific operational issue. A new batch of material is now expected in Q2 2027. As a result of this supply interruption, data from the Phase 1b/2 study is now expected in 2H 2027, which will include durability data from initial patient cohorts.\n\n* Kalaris has now successfully completed the technology transfer from the pilot manufacturer to KBI Biopharma, the drug substance manufacturer selected to deliver the planned commercial-scale supply. Test batches achieved the target specifications required for Phase 3 clinical development.\n\n* Potential initiation of a Phase 3 program is now expected in 2028, resulting in an extension of the anticipated cash runway into 2028 and beyond the preliminary Phase 1b/2 data readout. \"Kalaris made meaningful progress in the third quarter,\" said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics. \"We continue to enroll and dose nAMD patients in the ongoing Phase 1b/2 study. In addition to progressing the clinical trial, we have successfully completed the tech transfer to a new commercial-scale manufacturer, with initial test batches achieving the target specifications. Given the paramount importance of ensuring critical quality attributes at the scale required for Phase 3 and commercial supply, this was a significant accomplishment in Q3 and strengthens our confidence in our future clinical supply.\"\n\nFinancial Results for the Third Quarter Ended September 30, 2026\n\nCash, Cash Equivalents and Marketable Securities: As of September 30, 2026, Kalaris had cash, cash equivalents and marketable securities of $82.9 million, compared with cash, cash equivalents and marketable securities of $118.0 million as of December 31, 2025. The decrease in cash, cash equivalents and marketable securities was primarily a result of cash used in operating activities during the period. Based on its current operating plans, Kalaris expects that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into 2028.\n\nResearch and Development Expenses: Research and development expenses were $8.3 million for the quarter ended September 30, 2026, compared with $9.1 million for the quarter ended September 30, 2025. The decrease was primarily attributable to a decrease in manufacturing and process development activities, partially offset by an increase in contract research organization and other clinical expenses as Kalaris opened additional investigational sites and enrolled patients in its Phase 1b/2 clinical trial of TH103.\n\nGeneral and Administrative Expenses: General and administrative expenses were $3.5 million for the quarter ended September 30, 2026, compared with $3.6 million for the quarter ended September 30, 2025. The decrease was primarily attributable to a decrease in professional services, consulting and other general and administrative expenses, partially offset by an increase in personnel-related costs.\n\nNet Loss: For the quarter ended September 30, 2026, net loss was $11.0 million compared with a net loss of $11.9 million for the quarter ended September 30, 2025. The total number of shares of common stock outstanding as of September 30, 2026 was 23,804,981.\n\nAbout TH103\n\nTH103 is an investigational dual-targeting biologic with the potential to be best-in class for neovascular and exudative retinal diseases. TH103 was engineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve extended intraocular retention with enhanced VEGF inhibition through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed for intravitreal delivery, with potential applications as a treatment for exudative and/or neovascular retinal diseases, such as neovascular Age-related Macular Degeneration (nAMD), diabetic eye disease and retinal vein occlusion. TH103 is currently being investigated in a Phase 1b/2 clinical trial in patients with nAMD.\n\nAbout Kalaris\n\nKalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.\n\nFor more information, visit www.kalaristx.com.\n\nForward Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risk and uncertainties. All statements, other than statements of historical fact, contained in this press release, including statements regarding the strategy, future operations, future financial position, plans and objectives of management of Kalaris, the therapeutic potential of TH103 for neovascular age-related macular degeneration and other exudative and neovascular retinal diseases, the anticipated timeline for reporting data from the ongoing Phase 1b/2 clinical trial of TH103 and initiating Phase 3 clinical trials, plans to advance TH103 into Phase 3 clinical trials and to develop TH103 for additional indications, Kalaris' expectations regarding the anticipated timeline for obtaining a new batch of TH103 for use in its Phase 1b/2 clinical trial, Kalaris' expectations regarding the ability of its new commercial-scale drug substance manufacturer to supply sufficient TH103 drug substance meeting the quality standards and applicable regulatory requirements for clinical development and the sufficiency of Kalaris' cash resources for the period anticipated, are forward-looking statements. The words \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"would\" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on current expectations and beliefs of the management of Kalaris as well as assumptions made by, and information currently available to, the management of Kalaris and are subject to risks and uncertainties. There can be no assurance that future developments affecting Kalaris will be those that it has anticipated. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: risks associated with the clinical development and regulatory approval of TH103, including potential delays in the completion of clinical trials; expectations regarding the therapeutic benefits, clinical potential and clinical development of TH103; the timing of and Kalaris' ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; dependence on third parties for the development and manufacture of TH103 and their ability to supply sufficient TH103 drug substance meeting the quality standards and applicable regulatory requirements for clinical development; risks related to the inability of Kalaris to obtain sufficient additional capital to continue to advance its product candidate; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from any product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the ability to obtain, maintain, and protect intellectual property rights related to product candidates; changes in regulatory requirements and government incentives; Kalaris' competitive position and expectations regarding developments and projections relating to its competitors and any competing therapies that are or become available; the risk of involvement in current and future litigation; and such other factors as are set forth in Kalaris' public filings with the Securities and Exchange Commission, including, but not limited to, those described under the heading \"Risk Factors\". Kalaris may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release, and Kalaris does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.\n\nKalaris Therapeutics Investor Contact:\n\nCorey Davis, Ph.D.\n\nLifeSci Advisors, LLC\n\n+1 212 915 2577\n\nKalaris Therapeutics, Inc.Condensed Consolidated Statements of Operations(unaudited, in thousands, except share and per share data)\n\nThree Months Ended\n\nSeptember 30,\n\nNine Months Ended\n\nSeptember 30,\n\n2026\n\n2025\n\n2026\n\n2025\n\nOperating expenses Research and development $8,344 $9,126 $24,934 $23,596 General and administrative 3,467 3,615 11,096 11,755 Total operating expenses 11,811 12,741 36,030 35,351 Loss from operations (11,811) (12,741) (36,030) (35,351) Total other income, net 785 847 2,633 1,911 Net loss $(11,026) $(11,894) $(33,397) $ (33,440)Net loss per share, basic and diluted $(0.46) $(0.64) $ (1.40) $ (2.41)Weighted-average shares outstanding, basic and diluted 23,804,981 18,701,708 23,775,600 13,872,369\n\nKalaris Therapeutics, Inc.Condensed Consolidated Balance Sheets(unaudited, in thousands)\n\nSeptember 30, December 31, 2026\n\n2025\n\nAssets Current assets Cash, cash equivalents and marketable securities $82,856 $117,982Other current assets 2,320 827Total current assets 85,176 118,809Other assets 3,827 2,927Total assets $89,003 $121,736Liabilities and stockholders' equity Current liabilities $8,514 $9,714Long-term liabilities 33,087 33,208Total liabilities 41,601 42,922\n\nTotal stockholders' equity\n\n47,402 78,814Total liabilities and stockholders' equity $89,003 $121,736",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical",
"type": "wiki",
"score": 5,
"label": {
"eng": "Biopharmaceutical"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Kalari",
"type": "wiki",
"score": 5,
"label": {
"eng": "Kalari"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Neovascularization",
"type": "wiki",
"score": 5,
"label": {
"eng": "Neovascularization"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Deuterium",
"type": "wiki",
"score": 5,
"label": {
"eng": "Deuterium"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Technology_transfer",
"type": "wiki",
"score": 5,
"label": {
"eng": "Technology transfer"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Retina",
"type": "wiki",
"score": 5,
"label": {
"eng": "Retina"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Clinical_trial",
"type": "wiki",
"score": 5,
"label": {
"eng": "Clinical trial"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Security_(finance)",
"type": "wiki",
"score": 5,
"label": {
"eng": "Security (finance)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Exudate",
"type": "wiki",
"score": 4,
"label": {
"eng": "Exudate"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Drug_development",
"type": "wiki",
"score": 4,
"label": {
"eng": "Drug development"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Macular_degeneration",
"type": "wiki",
"score": 4,
"label": {
"eng": "Macular degeneration"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Nasdaq",
"type": "wiki",
"score": 3,
"label": {
"eng": "Nasdaq"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Napoleone_Ferrara",
"type": "person",
"score": 3,
"label": {
"eng": "Napoleone Ferrara"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor",
"type": "wiki",
"score": 3,
"label": {
"eng": "Vascular endothelial growth factor"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Efficacy",
"type": "wiki",
"score": 3,
"label": {
"eng": "Efficacy"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Cohort_study",
"type": "wiki",
"score": 3,
"label": {
"eng": "Cohort study"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Test_cricket",
"type": "wiki",
"score": 3,
"label": {
"eng": "Test cricket"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer",
"type": "wiki",
"score": 3,
"label": {
"eng": "Chief executive officer"
}
},
{
"uri": "http://en.wikipedia.org/wiki/GlobeNewswire",
"type": "org",
"score": 3,
"label": {
"eng": "GlobeNewswire"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Anti-VEGF",
"type": "wiki",
"score": 2,
"label": {
"eng": "Anti-VEGF"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Diabetes",
"type": "wiki",
"score": 2,
"label": {
"eng": "Diabetes"
}
},
{
"uri": "http://en.wikipedia.org/wiki/VEGF_receptor",
"type": "wiki",
"score": 2,
"label": {
"eng": "VEGF receptor"
}
}
],
"categories": [
{
"uri": "dmoz/Health",
"label": "dmoz/Health",
"wgt": 20
},
{
"uri": "dmoz/Science",
"label": "dmoz/Science",
"wgt": 21
},
{
"uri": "dmoz/Society/Issues",
"label": "dmoz/Society/Issues",
"wgt": 21
},
{
"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Pharmaceuticals",
"label": "dmoz/Business/Biotechnology and Pharmaceuticals/Pharmaceuticals",
"wgt": 26
},
{
"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Contract_Research_Organizations",
"label": "dmoz/Business/Biotechnology and Pharmaceuticals/Contract Research Organizations",
"wgt": 35
},
{
"uri": "news/Business",
"label": "news/Business",
"wgt": 100
},
{
"uri": "iptc/economy,_business_and_finance/business_information",
"label": "iptc/economy, business and finance/business information",
"wgt": 100
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300523.jpg",
"eventUri": null,
"sentiment": 0.2078431372549019,
"wgt": 532010543,
"relevance": 1
},
{
"uri": "9538477737",
"lang": "eng",
"isDuplicate": false,
"date": "2026-11-10",
"time": "12:42:23",
"dateTime": "2026-11-10T12:42:23Z",
"dateTimePub": "2026-11-10T12:36:21Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/goguardian-launches-goguardian-visitor-delivering-the-most-complete-visitor-management-solution-in-k-12/2466292",
"title": "GoGuardian Launches GoGuardian Visitor, Delivering the Most Complete Visitor Management Solution in K-12",
"body": "Built by the brand that defined K-12 digital safety, GoGuardian Visitor protects students and staff with visitor screening and check-in that's easy, fast, and reliable. One flat price per site, per year covers it all, with no new hardware and no add-on fees\n\nLOS ANGELES, Nov. 10, 2026 (GLOBE NEWSWIRE) -- GoGuardian, the brand that defined K-12 digital safety, supporting more than 25 million students and 10,000 schools nationwide, today announced its expansion into physical safety with the launch of GoGuardian Visitor, the most complete visitor management solution in K-12. Built to work more reliably than any solution on the market, GoGuardian Visitor keeps campus safer with a customizable check-in experience that is easy to use and works seamlessly on the devices schools already have - all for one flat price per site, per year.\n\nEvery visitor check-in is a safety decision, so every out-of-service kiosk or extra vendor charge forces schools to compromise. GoGuardian Visitor removes that compromise: every feature included, unlimited check-in stations, and nothing extra to buy.\n\n\"We've spent more than a decade earning schools' trust by protecting students online. Physical safety was the logical extension to further our mission and continue to lead the way in keeping students safe,\" said Rich Preece, CEO of GoGuardian. \"So we built the most complete visitor management solution in K-12 and priced it so no school has to sacrifice safety because of budget.\"\n\nOne reliable screening standard at every building:\n\n* One standard, with schools in control. Districts apply consistent screening against sex offender records and custom watchlists at every building while schools keep ownership of their data and control over what visitor data is stored, all from the company schools already trust with their most sensitive information.\n\n* Seamless check-in. Fully customizable workflows for simple self-service or staff-assisted check-in with photo capture, ID scanning, and automatic multi-language support. Integration with GoGuardian Hall Pass means passes are created automatically at student check-in or pickup, and visitor and student passes appear in one live view.\n\n* Deep insights. Daily and weekly reports provide visitor history data, and AI flags anomalies and patterns and answers questions in plain English, so the record of who was on campus is accurate and easy to use.\n\n* Everything included. Every feature and unlimited kiosks come in one flat price per site, per year. GoGuardian Visitor runs on the Chromebooks, iPads, and Windows devices schools already own and with most existing badge printers, so there is no hardware to buy and no add-on fee to add a check-in point. \"We built this to be seamless for IT, from first setup to everyday use. No hardware to buy. No per-kiosk licenses to track. No add-on fees to chase,\" said Tyler Shaddix, Co-Founder & Chief Innovation Officer at GoGuardian. \"When the most complete solution on the market is also the easiest one to roll out and the least expensive to own, there's no decision left to agonize over.\"\n\nIntegrated with the Hall Pass system schools already run\n\nGoGuardian Visitor works seamlessly with GoGuardian Hall Pass, so the classrooms, staff, and students IT has already set up are ready on day one. When a student is checked in or picked up, a pass is created automatically. That means one setup instead of another standalone system to integrate, secure, and support.\n\nEvery feature. Unlimited kiosks. One flat price per site, per year. GoGuardian Visitor is available now at goguardian.com/visitor.\n\nAbout GoGuardian\n\nWith over a decade of experience, including pioneering the use of AI in K-12 education, GoGuardian delivers best-in-class solutions built with educators, not just for them. Our suite of products, powered by purpose-driven, customizable AI and actionable insights, enables what matters most: safer schools, empowered teachers, and thriving students. Trusted by over 2 million educators and more than 10,000 schools, GoGuardian supports 25 million students nationwide-representing 50% of all public and private K-12 learners in the U.S.\n\nGoGuardian's curriculum and instruction suite, Pear Deck Learning, is the only platform that offers teachers support for every instructional step in any topic-all in one place. From lesson planning to state testing, Pear Deck Learning helps teachers deliver engaging instruction, personalized learning tailored to each student's needs, and meaningful assessment all with ease.",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/GoGuardian",
"type": "org",
"score": 5,
"label": {
"eng": "GoGuardian"
}
},
{
"uri": "http://en.wikipedia.org/wiki/K–12",
"type": "wiki",
"score": 5,
"label": {
"eng": "K–12"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Internet_safety",
"type": "wiki",
"score": 5,
"label": {
"eng": "Internet safety"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Plug-in_(computing)",
"type": "wiki",
"score": 4,
"label": {
"eng": "Plug-in (computing)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Information_technology",
"type": "wiki",
"score": 2,
"label": {
"eng": "Information technology"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Artificial_intelligence",
"type": "wiki",
"score": 2,
"label": {
"eng": "Artificial intelligence"
}
},
{
"uri": "http://en.wikipedia.org/wiki/English_language",
"type": "wiki",
"score": 2,
"label": {
"eng": "English language"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer",
"type": "wiki",
"score": 2,
"label": {
"eng": "Chief executive officer"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Pear_Deck",
"type": "org",
"score": 1,
"label": {
"eng": "Pear Deck"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chromebook",
"type": "wiki",
"score": 1,
"label": {
"eng": "Chromebook"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Curriculum",
"type": "wiki",
"score": 1,
"label": {
"eng": "Curriculum"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Microsoft_Windows",
"type": "wiki",
"score": 1,
"label": {
"eng": "Microsoft Windows"
}
},
{
"uri": "http://en.wikipedia.org/wiki/IPad",
"type": "wiki",
"score": 1,
"label": {
"eng": "IPad"
}
}
],
"categories": [
{
"uri": "dmoz/Computers/Software/Internet",
"label": "dmoz/Computers/Software/Internet",
"wgt": 19
},
{
"uri": "dmoz/Science/Technology/Safety_Engineering",
"label": "dmoz/Science/Technology/Safety Engineering",
"wgt": 18
},
{
"uri": "dmoz/Computers/Software/Online_Training",
"label": "dmoz/Computers/Software/Online Training",
"wgt": 21
},
{
"uri": "dmoz/Society/Issues/Education",
"label": "dmoz/Society/Issues/Education",
"wgt": 24
},
{
"uri": "dmoz/Computers/Software/Educational",
"label": "dmoz/Computers/Software/Educational",
"wgt": 24
},
{
"uri": "news/Technology",
"label": "news/Technology",
"wgt": 78
},
{
"uri": "iptc/economy,_business_and_finance",
"label": "iptc/economy, business and finance",
"wgt": 80
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300525.png",
"eventUri": null,
"sentiment": 0.4666666666666666,
"wgt": 532010543,
"relevance": 1
},
{
"uri": "9538477740",
"lang": "eng",
"isDuplicate": false,
"date": "2026-11-10",
"time": "12:42:20",
"dateTime": "2026-11-10T12:42:20Z",
"dateTimePub": "2026-11-10T12:36:04Z",
"dataType": "news",
"sim": 0,
"url": "https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/habit-co-welcomes-chef-and-creator-olivia-tiedemann-as-its-third-culinary-resident/2466289",
"title": "Habit & Co. Welcomes Chef and Creator Olivia Tiedemann as its Third Culinary Resident",
"body": "The no-nonsense chef and creator brings her dry humor, sharp point of view and steakhouse-inspired menu to Habit\n\nHabit & Co. Welcomes Chef and Creator Olivia Tiedemann as its Third Culinary Resident\n\nThe no-nonsense chef and creator brings her dry humor, sharp point of view and steakhouse-inspired menu to Habit.\n\nIRVINE, Calif., Nov. 10, 2026\n\n(GLOBE NEWSWIRE) -- Habit is welcoming chef and creator Olivia Tiedemann as the third resident in Habit & Co., its culinary residence program built around bringing distinctive culinary voices to the Habit menu. Tiedemann's limited-time menu will be available from November 11, 2026 through January 7, 2027.\n\nKnown for her dry sense of humor, no-nonsense approach to cooking and a point of view that is very much her own, Tiedemann brings that attitude to a menu built around steakhouse flavors and a serious amount of peppercorn sauce.\n\n\"We wanted a menu with sass, and Olivia definitely has that,\" said Jack Lettenmair, Habit's Director of Brand Marketing. \"She has a very distinct point of view, and you can taste it in this menu. We gave her room to have fun with some big steakhouse flavors, and she came back with exactly what we were hoping for.\"\n\nOlivia's Habit & Co. menu includes:\n\nSteakhouse Peppercorn Char: Freshly chargrilled beef patty topped with baby Swiss cheese, Portabella mushrooms, crispy onion tanglers, fresh tomato, green leaf lettuce and peppercorn sauce on a toasted brioche bun.\n\nSteakhouse Peppercorn Salad: Chargrilled sirloin steak, heritage greens, Portabella mushrooms, crispy onion tanglers, aged white cheddar, tomatoes, cucumbers and croutons, finished with a drizzle of peppercorn sauce and served with a side of house balsamic dressing.\n\nParmesan-Crusted Mozz Tots: Golden, crispy tots filled with mozzarella cheese, served with a side of peppercorn sauce.\n\n\"I wanted this menu to feel 'steakhouse,' but more fun and less serious,\" Tiedemann said. \"All the familiar steakhouse flavors in an approachable, casual way. With a shit ton of peppercorn sauce. And no mayo. Obviously.\"\n\nThe menu brings Tiedemann's steakhouse-inspired point of view into Habit's kitchen, with freshly chargrilled proteins, crisp toppings and plenty of peppercorn sauce throughout.\n\nHabit & Co. launched with Chef Jet Tila as its first culinary resident, bringing his Korean Street Menu to Habit, followed up by Dodger's pitcher Alex Vesia's Double Play Menu. The program gives chefs and creators a chance to put their own spin on Habit favorites while working within the brand's fresh, cooked-to-order approach.\n\nFor more information about Habit and to find a restaurant near you, visit www.habitburger.com. Connect with Habit on social media on Instagram, Facebook, TikTok and LinkedIn\n\nAbout Habit Burger & Grill\n\nBorn in sunny Southern California in 1969, Habit Burger & Grill has been serving up fresh, cooked-to-order favorites for more than 55 years. Best known for its signature Charburgers, grilled over an open flame, Habit brings a distinctly California-inspired approach to fast casual dining with a menu that goes far beyond burgers, including handcrafted sandwiches, crisp salads, creamy shakes, and fan-favorite sides.\n\nHabit continues to earn national recognition for its fresh flavor and quality. The brand's Double Char was ranked #1 by USA TODAY¹ 10Best three years running, its Tempura Green Beans earned the #1 spot in USA TODAY 10Best² in 2024 and 2025, and Habit was named the #1 Fast Casual Restaurant by USA TODAY 10Best³ in 2025 and 2026. The brand's Chicken Club was also recognized as the best grilled chicken sandwich by The Daily Meal⁴, and Habit has been featured in Newsweek's \"America's Favorite Restaurant Chains 2023\" and Thrillist's roundup of \"Underrated Burger Chains That Need to Be in Every State.\" Today, Habit Burger & Grill has grown to more than 385 restaurants across 14 states as well as a fleet of food trucks, continuing to serve bold, fresh flavors that are always cooked to order. Learn more at www.habitburger.com.\n\nLearn more at www.habitburger.com\n\n¹Based on USA Today 10Best Readers' Choice 2024 Awards for Best Fast Food Burger. (Published July 2024, 2025 & 2026).\n\n²Based on USA Today 10Best Readers' Choice 2024 Awards for Best Fast Food Sides. (Published July 2024 & 2025).\n\n³Based on USA Today 10Best Readers' Choice 2024 Awards for Best Fast Casual Restaurant. (Published July 2025, July 2026).\n\n⁴Based on Daily Meal's survey of consumer reviews from Reddit, Yelp! and TripAdvisor (Published Dec. 2023).\n\nHabit Burger & Grill Press Contact: [email protected]\n\nA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f7f7318-0fa2-4531-81b9-2fa584942a1b",
"source": {
"uri": "manilatimes.net",
"dataType": "news",
"title": "The Manila times"
},
"authors": [],
"concepts": [
{
"uri": "http://en.wikipedia.org/wiki/Peppercorn_sauce",
"type": "wiki",
"score": 5,
"label": {
"eng": "Peppercorn sauce"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Steakhouse",
"type": "wiki",
"score": 5,
"label": {
"eng": "Steakhouse"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Chef",
"type": "wiki",
"score": 5,
"label": {
"eng": "Chef"
}
},
{
"uri": "http://en.wikipedia.org/wiki/The_Resident_(TV_series)",
"type": "wiki",
"score": 5,
"label": {
"eng": "The Resident (TV series)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Mushroom",
"type": "wiki",
"score": 3,
"label": {
"eng": "Mushroom"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Onion",
"type": "wiki",
"score": 3,
"label": {
"eng": "Onion"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Tomato",
"type": "wiki",
"score": 3,
"label": {
"eng": "Tomato"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Salad",
"type": "wiki",
"score": 3,
"label": {
"eng": "Salad"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Marketing",
"type": "wiki",
"score": 3,
"label": {
"eng": "Marketing"
}
},
{
"uri": "http://en.wikipedia.org/wiki/GlobeNewswire",
"type": "org",
"score": 3,
"label": {
"eng": "GlobeNewswire"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Swiss_cheese_(North_America)",
"type": "wiki",
"score": 2,
"label": {
"eng": "Swiss cheese (North America)"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Jet_Tila",
"type": "person",
"score": 2,
"label": {
"eng": "Jet Tila"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Leaf_vegetable",
"type": "wiki",
"score": 2,
"label": {
"eng": "Leaf vegetable"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Patty",
"type": "wiki",
"score": 2,
"label": {
"eng": "Patty"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Sirloin_steak",
"type": "wiki",
"score": 2,
"label": {
"eng": "Sirloin steak"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Brioche",
"type": "wiki",
"score": 2,
"label": {
"eng": "Brioche"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Balsamic_vinegar",
"type": "wiki",
"score": 2,
"label": {
"eng": "Balsamic vinegar"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Bun",
"type": "wiki",
"score": 2,
"label": {
"eng": "Bun"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Crouton",
"type": "wiki",
"score": 2,
"label": {
"eng": "Crouton"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Mozzarella",
"type": "wiki",
"score": 2,
"label": {
"eng": "Mozzarella"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Cucumber",
"type": "wiki",
"score": 2,
"label": {
"eng": "Cucumber"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Lettuce",
"type": "wiki",
"score": 2,
"label": {
"eng": "Lettuce"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Yelp",
"type": "org",
"score": 1,
"label": {
"eng": "Yelp"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Reddit",
"type": "org",
"score": 1,
"label": {
"eng": "Reddit"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Instagram",
"type": "org",
"score": 1,
"label": {
"eng": "Instagram"
}
},
{
"uri": "http://en.wikipedia.org/wiki/Southern_California",
"type": "loc",
"score": 1,
"label": {
"eng": "Southern California"
},
"location": null
},
{
"uri": "http://en.wikipedia.org/wiki/Facebook",
"type": "org",
"score": 1,
"label": {
"eng": "Facebook"
}
},
{
"uri": "http://en.wikipedia.org/wiki/LinkedIn",
"type": "org",
"score": 1,
"label": {
"eng": "LinkedIn"
}
}
],
"categories": [
{
"uri": "dmoz/Business/Hospitality",
"label": "dmoz/Business/Hospitality",
"wgt": 26
},
{
"uri": "dmoz/Home/Cooking/Chefs",
"label": "dmoz/Home/Cooking/Chefs",
"wgt": 23
},
{
"uri": "dmoz/Home/Cooking/Sandwiches",
"label": "dmoz/Home/Cooking/Sandwiches",
"wgt": 29
},
{
"uri": "dmoz/Recreation/Food/Dining_Guides",
"label": "dmoz/Recreation/Food/Dining Guides",
"wgt": 21
},
{
"uri": "dmoz/Recreation/Food/Fast_Food",
"label": "dmoz/Recreation/Food/Fast Food",
"wgt": 30
},
{
"uri": "news/Arts_and_Entertainment",
"label": "news/Arts and Entertainment",
"wgt": 100
},
{
"uri": "iptc/economy,_business_and_finance",
"label": "iptc/economy, business and finance",
"wgt": 74
}
],
"image": "https://manilatimes.net/manilatimes/uploads/images/2026/11/10/1300520.jpg",
"eventUri": null,
"sentiment": 0.3254901960784313,
"wgt": 532010540,
"relevance": 1
}
],
"totalResults": 45023,
"page": 1,
"count": 10,
"pages": 4503
}
}